EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital Clínico San Carlos de Madrid (16)
2024
-
Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management
Clinical and Translational Oncology
2023
2022
2021
2020
-
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428
-
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
Future Oncology, Vol. 16, Núm. 33, pp. 2763-2778
-
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)
Breast Cancer Research and Treatment, Vol. 184, Núm. 2, pp. 469-479
2019
-
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project
Cancer Chemotherapy and Pharmacology, Vol. 83, Núm. 2, pp. 301-318
-
SEOM clinical guidelines in early stage breast cancer (2018)
Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 18-30
-
Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study
Breast Journal, Vol. 25, Núm. 2, pp. 219-225
2018
-
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain
Clinical and Translational Oncology, Vol. 20, Núm. 6, pp. 753-760
2016
-
Single arm, multicentre, non-randomized open-label trial to evaluate the safety of eribulin in third line chemotherapy in patients with HER2-negative metastatic or locally advanced breast cancer previously treated with anthracyclines and taxanes: Onsite study (ONCOSUR 2012-02)
Annals of Oncology, Vol. 27, pp. vi76
2015
-
SEOM clinical guidelines in early-stage breast cancer 2015
Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 939-945
2014
-
Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer
Journal of Cancer Research and Therapeutics, Vol. 10, Núm. 4, pp. 967-972
2012
-
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: A phase II study evaluating co-treatment with dexamethasone
Investigational New Drugs, Vol. 30, Núm. 2, pp. 729-740
2006
-
Vinflunine: A new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy
British Journal of Cancer, Vol. 95, Núm. 9, pp. 1161-1166